🇺🇸 FDA
Patent

US 10844384

Glucokinase (GCK) iRNA compositions and methods of use thereof

granted A61KA61K31/713A61K45/06

Quick answer

US patent 10844384 (Glucokinase (GCK) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
38
CPC classes
A61K, A61K31/713, A61K45/06